Weiping Wu1,2, Lifen Chen1,2, Yanzhong Wang1, Jing Jin1,2, Xinyou Xie1, Jun Zhang1. 1. Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou. 2. Department of Clinical Laboratory, Lishui People's Hospital, Lishui, Zhejiang, China.
Abstract
BACKGROUND: Hyaluronic acid (HA) may be a novel prognostic biomarker of breast cancer. However, the available evidence is controversial. Therefore, we performed a meta-analysis to determine the prognostic role of HA in breast cancer. METHODS: The data were extracted from seven articles by searching the databases of PubMed, EMBASE, Web of Science, the Chinese National Knowledge Infrastructure and Wanfang data for the prognostic role of HA in breast cancer. In reference to survival outcomes, the pooled hazard ratios (HRs) of HA were calculated given a 95% confidence interval (CI). RESULTS: A total of seven articles were included in our study involving 2664 cases. The result of meta-analysis showed that a high HA level predicts poor overall survival (OS) (HR = 1.86, 95% CI: 1.28-2.71, P = .001) and shortened disease-free or recurrence-free survival or progression free survival (DFS/RFS/PFS) (HR = 1.63, 95% CI: 1.14-2.33, P = .007) in breast cancer patients. Moreover, a high HA level in stroma (HR = 1.63, 95% CI: 1.06-2.51, P = .025) and plasma (HR = 3.26, 95% CI: 2.25-4.73, P < .001) significantly predicted poor OS. Besides, a tendency shows that HA was significantly correlated with lymph node metastasis (HR = 1.55, 95% CI: 0.96-2.49, P = .070) and tumor grade (HR = 2.10, 95% CI: 0.89-4.96, P = .089) on the clinical characteristics of patients. CONCLUSION: These results suggested that HA has a potential to be prognostic biomarker in breast cancer patients, especially location in stroma and plasma.
BACKGROUND:Hyaluronic acid (HA) may be a novel prognostic biomarker of breast cancer. However, the available evidence is controversial. Therefore, we performed a meta-analysis to determine the prognostic role of HA in breast cancer. METHODS: The data were extracted from seven articles by searching the databases of PubMed, EMBASE, Web of Science, the Chinese National Knowledge Infrastructure and Wanfang data for the prognostic role of HA in breast cancer. In reference to survival outcomes, the pooled hazard ratios (HRs) of HA were calculated given a 95% confidence interval (CI). RESULTS: A total of seven articles were included in our study involving 2664 cases. The result of meta-analysis showed that a high HA level predicts poor overall survival (OS) (HR = 1.86, 95% CI: 1.28-2.71, P = .001) and shortened disease-free or recurrence-free survival or progression free survival (DFS/RFS/PFS) (HR = 1.63, 95% CI: 1.14-2.33, P = .007) in breast cancerpatients. Moreover, a high HA level in stroma (HR = 1.63, 95% CI: 1.06-2.51, P = .025) and plasma (HR = 3.26, 95% CI: 2.25-4.73, P < .001) significantly predicted poor OS. Besides, a tendency shows that HA was significantly correlated with lymph node metastasis (HR = 1.55, 95% CI: 0.96-2.49, P = .070) and tumor grade (HR = 2.10, 95% CI: 0.89-4.96, P = .089) on the clinical characteristics of patients. CONCLUSION: These results suggested that HA has a potential to be prognostic biomarker in breast cancerpatients, especially location in stroma and plasma.
Authors: Qinghua Xu; Jessica E Torres; Mazin Hakim; Paulina M Babiak; Pallabi Pal; Carly M Battistoni; Michael Nguyen; Alyssa Panitch; Luis Solorio; Julie C Liu Journal: Mater Sci Eng R Rep Date: 2021-07-30 Impact factor: 33.667
Authors: Josephine A Hinneh; Joanna L Gillis; Nicole L Moore; Lisa M Butler; Margaret M Centenera Journal: Front Oncol Date: 2022-08-10 Impact factor: 5.738